13 Feb 2026
DER AKTIONÄR interviews COO Sebastian Schwertlein on Clusterix and international expansion
DER AKTIONÄR features an interview with COO Sebastian Schwertlein on innoscripta’s development since the IPO, the technological positioning of the all-in-one platform Clusterix and the company’s expansion plans in Germany and across Europe. The discussion highlights platform differentiation, integrated R&D process tools and strategic growth priorities for the coming years.
You Might Also Like
28 Sept 2026
DER AKTIONÄR on innoscripta’s growth, international scaling and AI strategy
DER AKTIONÄR interviews CFO Alexander Meyer and COO Sebastian Schwertlein about innoscripta’s operational development, international growth and continued expansion of its software systems. The interview covers the 43% increase in revenue and 49% rise in EBIT in the first half of 2026, expansion into the United Kingdom, France and the US, and the role of AI in making internal workflows more efficient.Read more: https://www.deraktionaer.de/artikel/aktien/geheime-ki-gewinner-kennen-sie-diese-deutsche-aktie-20409622.html
01 Oct 2026
The data layer of German research: Clusterix reaches a scale equivalent to more than 10% of Germany’s R&D workforce
Almost one in three large companies with an approved Research Allowance in 2025 is an innoscripta customer – Clusterix makes research and development transparent and the utilisation of tax-based R&D funding predictable, efficient and audit-proof.What happens every day on the Clusterix platform of innoscripta SE (ISIN: DE000A40QVM8) represents a real-time snapshot of Germany’s research landscape: the research and development activities of around 70,000 R&D employees at German companies – more than 10%, measured against the number of R&D employees in the German business sector¹ – are recorded, structured and documented in an audit-proof manner on the platform. In the large-company segment, where the requirements for audit-proof evidence are highest, 31% of all companies with a certified Research Allowance² in 2025 were innoscripta customers. In total, the company serves more than 2,900 customers in Europe and North America – with a cumulative cancellation rate of less than 5% since the programme was launched in 2020³.The platform: Transparency instead of flying blindThe Research Allowance is a statutory entitlement – but between entitlement and payment lies a hurdle at which many companies fail: providing audit-proof evidence. Companies that do not comprehensively document projects, activities and hours risk, in the worst case, reductions and repayment claims during a tax audit – or, out of caution, forgo funding to which they are entitled altogether. This is precisely the gap that Clusterix closes: the platform connects customers’ project data, time tracking and commercial systems to create an end-to-end, AI-supported documentation process. This makes R&D visible in real time for the first time – both to management and to the tax authorities. The result: companies can claim their entitlements efficiently, predictably and with minimised audit risk, rather than leaving funding unclaimed due to uncertainty.“The employees recorded in Clusterix correspond to a scale equivalent to more than 10% of the entire R&D workforce in Germany – and these people do not conduct research retrospectively, but anew every year,” says Michael Hohenester, founder and CEO of innoscripta SE. “Clusterix is the data layer between companies conducting research and the tax authorities. We turn a process regarded as a bureaucratic monster into a predictable standard: transparent for the company, supported by robust evidence for the auditor. Every financial year generates new projects, new documentation obligations and new entitlements – and that is precisely what our business model is built around.”A growing market with tailwindsThe legislator is continuously expanding the Research Allowance: since 1 January 2026, a maximum assessment basis of €12 million per financial year has applied, supplemented by a flat-rate overhead allowance of 20%. The greater the funding, the higher the requirements for documentation – and the more valuable a platform that connects the two becomes. Through Clusterix, innoscripta also covers adjacent CFO-office compliance processes, including transfer pricing documentation, and is extending the model to international R&D incentive regimes in markets such as France and the United Kingdom.Key figures at a glanceAround 70,000 R&D employees (headcount) with documented R&D activity on the platform – around one in ten R&D employees in the German business sector¹31% of all large companies with a certified Research Allowance in 2025 are innoscripta customers²More than 2,900 customers in Europe and North America (as at 30 June 2026)Cumulative cancellation rate since 2020: less than 5%¹ Based on 632,551 employees working in research and development (R&D) in the German business sector in 2023. Definitions of R&D personnel may differ; the comparison is intended solely to provide context for the relative scale.² Based on official BSFZ statistics for 2025, published by the Federal Ministry of Research, Technology and Space (BMFTR), as well as internal customer data and analyses by the company’s management. The classification is based on the European Commission’s SME definition; companies with 250 or more employees are classified as large companies, subject to the additional criteria of the EU SME definition.³ The cumulative customer churn rate since 2020 refers to the total number of customer contracts for which notice of termination had been received by 30 June 2026 – including contracts that remain active until the end of their respective contractual terms – divided by the sum of existing customer contracts and customer contracts newly concluded during the reporting period.About innoscriptainnoscripta SE, headquartered in Tutzing, is a leading provider of software for audit-proof R&D and tax compliance. The Clusterix platform makes companies’ research and development activities transparent and connects them with the documentation requirements of tax-based R&D incentives and adjacent CFO-office compliance processes. innoscripta serves more than 2,900 companies in Europe and North America. The shares of innoscripta SE (ISIN: DE000A40QVM8) are listed in the Scale segment of the Frankfurt Stock Exchange. innoscripta SE does not provide tax advisory services; tax advice and representation for customers are provided by their tax advisers.Contactinnoscripta SE | Max Hunger, Head of Investor Relations | ir@innoscripta.com | +49/89-25555-3509 | www.innoscripta.com
